我要投票 九芝堂在阿胶行业中的票数:628
· 外 推 电 报 ·
2025-08-20 21:45:25 星期三

【九芝堂是哪个国家的品牌?】

九芝堂是什么牌子?「九芝堂」是 九芝堂股份有限公司 旗下著名品牌。该品牌发源于湖南省长沙市,由创始人李振国在1999-05-12期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力九芝堂品牌出海!将品牌入驻外推网,定制九芝堂品牌推广信息,可以显著提高九芝堂产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

九芝堂股份有限公司是国家重点中药企业,国内A股上市公司,湖南省重点高新技术企业,湖南省百强企业,湖南省质量管理奖企业,长沙市工业十大标志性工程龙头企业,国家博士后科研工作站企业。

九芝堂前身“劳九芝堂药铺”创建于1650年。2004年2月,“九芝堂”商标被国家工商行政管理总局商标局认定为中国驰名商标;2006年9月,“九芝堂”被国家商务部认定为“中华老字号”;2008年6月,九芝堂传统中药文化被列入国家级非物质文化遗产保护目录。

截至2009年底,公司已发展成为拥有总资产15.48亿元,净资产12.57亿元,下辖7家直接控股子公司、3家间接控股子公司,1家分公司,年销售过12亿元,利税过3亿元的工商一体化的现代大型医药企业。

公司主要从事补血系列、补益系列、肝炎系列等中药以及调节人体免疫力的生物制剂的生产与销售,正在形成销售过亿产品、过千万产品、迅速成长产品构成的一个产品阶梯,为可持续发展奠定了产品基础。主导产品驴胶补血颗粒年销售收入超过3亿元,位于全国天然补血类产品销售前三名;以六味地黄丸为代表的浓缩丸系列销售收入突破2亿元,位于全国同种产品销售前三名;斯奇康注射液销售收入1亿元。公司的中成药片剂、浓缩丸系列产品等出口欧美、日本、东南亚等地区,其中十多种浓缩丸、片剂出口日本已将近20年。九芝堂的产品不仅是济世良药,也是一种文化载体,九芝堂人不仅是客商,也成为了文化使节。

公司综合经济实力在湖南省医药行业中排名第一,已成为湖南省“十一五”重点发展的现代中药及生物医药优势产业集群的核心企业。2006年8月,在“首届中华老字号品牌价值百强榜”上,九芝堂以13.55亿的品牌价值排在第13位。2007年4月,九芝堂被《医药经济报》评为“中国制药工业企业百强”。2008年12月,公司通过湖南省科学技术厅的再认定,蝉联“高新技术企业”称号。

“九州共济、芝兰同芳”,面对激烈的市场竞争,九芝堂谋求和谐合作,共同发展。九芝堂将秉承三百多年优良的制药传统,把自主创新作为推动公司可持续发展的主导力量,立足民生、民情,发展现代中药产业,适度介入生物制品,开发消费者最为需要的产品,改善人类健康生活,致力于成为百亿市值企业。

英文翻译:Jiuzhitang Co., Ltd. is a national key traditional Chinese medicine enterprise, A-share listed company in China, key high-tech enterprise in Hunan Province, top 100 enterprise in Hunan Province, quality management award enterprise in Hunan Province, ten leading industrial engineering enterprises in Changsha City, and National Postdoctoral Research Station enterprise. The predecessor of Jiuzhitang, laojiuzhitang pharmacy, was founded in 1650. In February 2004, the trademark of "Jiuzhitang" was recognized as a well-known trademark by the Trademark Office of the State Administration for Industry and commerce; in September 2006, the trademark of "Jiuzhitang" was recognized as a "Chinese time-honored brand" by the Ministry of Commerce; in June 2008, the traditional Chinese medicine culture of Jiuzhitang was listed in the national intangible cultural heritage protection catalogue. By the end of 2009, the company has developed into a modern large-scale pharmaceutical enterprise with total assets of 1.548 billion yuan and net assets of 1.257 billion yuan. It has seven directly controlled subsidiaries, three indirectly controlled subsidiaries and one branch, with annual sales of 1.2 billion yuan and profits and taxes of 300 million yuan. The company is mainly engaged in the production and sales of traditional Chinese medicine such as blood tonic series, tonic series, hepatitis series and biological preparations regulating human immunity. It is forming a product ladder consisting of over 100 million products, over 10 million products and rapidly growing products, laying a product foundation for sustainable development. The annual sales revenue of lvjiao Buxue granules, the leading product, is more than 300 million yuan, which is located in the top three sales of natural Buxue products in China; the sales revenue of concentrated pill series represented by Liuwei Dihuang pill is more than 200 million yuan, which is located in the top three sales of the same kind of products in China; the sales revenue of Siqikang injection is 100 million yuan. The company's Chinese patent medicine tablets and concentrated pill series products are exported to Europe, America, Japan, Southeast Asia and other regions, among which more than ten kinds of concentrated pills and tablets have been exported to Japan for nearly 20 years. Jiuzhitang's products are not only good medicine for the world, but also a cultural carrier. Jiuzhitang people are not only merchants, but also cultural envoys. The company's comprehensive economic strength ranks first in the pharmaceutical industry of Hunan Province, and it has become the core enterprise of modern Chinese medicine and biomedical industry cluster which is the key development of "11th Five Year Plan" in Hunan Province. In August 2006, Jiuzhitang ranked 13th in the "top 100 list of brand value of the first time-honored Chinese brands". In April 2007, Jiuzhitang was named "top 100 pharmaceutical enterprises in China" by pharmaceutical economic news. In December 2008, the company passed the reappraisal of science and Technology Department of Hunan Province and won the title of "high and new technology enterprise". In the face of fierce market competition, Jiuzhitang seeks for harmonious cooperation and common development. Jiuzhitang will adhere to the excellent pharmaceutical tradition of more than three hundred years, take independent innovation as the leading force to promote the sustainable development of the company, based on the people's livelihood and the people's conditions, develop the modern Chinese medicine industry, moderately intervene in biological products, develop the products most needed by consumers, improve the healthy life of human beings, and strive to become a 10 billion market value enterprise.

本文链接: https://www.waitui.com/brand/7e3ceb284.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

江波龙:员工持股平台拟合计减持公司不超1.31%股份

36氪获悉,江波龙公告,龙熹一号、龙熹二号、龙熹三号、龙舰管理、龙熹五号(统称“员工持股平台”)合计持有公司16.53%股份,计划在2025年9月11日至12月10日期间通过集中竞价交易方式和大宗交易方式合计减持公司股份不超过548万股(不超过公司总股本的1.31%)。

2小时前

云南锗业:公司及鑫耀公司目前并无6英寸磷化铟晶片规模化量产的具体计划

36氪获悉,云南锗业发布股票交易异常波动公告,公司了解到,近期有国内研发机构发布了其在6英寸磷化铟外延生长工艺领域实现了技术突破相关事宜。就控股子公司鑫耀公司而言,在2-4英寸规格的磷化铟晶片量产后,为应对未来的市场需求,对更大尺寸的产品开展了研究开发,但从研发到规模化生产尚存在较大不确定性。公司及鑫耀公司目前并无6英寸磷化铟晶片规模化量产的具体计划,下一步在市场与需求风险、技术风险等可控的前提下,公司方会考虑相关计划,如有相关计划,公司会按规定进行公开披露。

2小时前

胜宏科技:向香港联交所递交H股发行并上市申请并刊发申请资料

36氪获悉,胜宏科技公告,公司已于2025年8月20日向香港联交所递交了发行境外上市股份(H股)并在香港联交所主板挂牌上市的申请,并于同日在香港联交所网站刊登了本次发行的申请资料。该申请资料为草拟版本,其所载资料可能会适时作出更新及修订。公司本次发行尚需取得相关政府机关、监管机构、证券交易所的批准、核准或备案。

2小时前

永辉超市:上半年净亏损2.41亿元

36氪获悉,永辉超市公告,公司上半年实现营业总收入299.48亿元,同比下降20.73%;净亏损2.41亿元,上年同期盈利2.75亿元。

2小时前

摩根大通与三菱日联接近达成220亿美元的得州数据中心融资协议

英国《金融时报》周三报道,摩根大通和日本三菱日联金融集团正就为得克萨斯州一个数据中心承销220亿美元贷款展开谈判。报道称,该规划中的园区将由Vantage Data Centers所有,这是一家由银湖资本和资产管理公司DigitalBridge 控股的数字基础设施企业。报道还指出,银湖资本和DigitalBridge将合计承诺30亿美元股权,助力该数据中心园区的建设。(新浪财经)

2小时前

本页详细列出关于九芝堂的品牌信息,含品牌所属公司介绍,九芝堂所处行业的品牌地位及优势。
咨询